GB08
Phase 3Small molecule
GB08 is one of 6 small molecule programs targeting Growth Hormone Deficiency. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Growth Hormone Deficiency
#DrugCompanyPhaseTrials
1Genotropin
EMD SeronoApproved
LUM-201
LLumos Pharma
Phase 3
GB08
SShenzhen Kexing Pharmaceutical Co., Ltd.
Phase 3
Somavert
PPharmacia and Upjohn
Preclinical
Somatrogon
PfizerPreclinical
Growth Hormone-Releasing Hormone
MMassachusetts General Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GB08. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details